Cilostazol inhibits the redistribution of the actin cytoskeleton and junctional proteins on the blood-brain barrier under hypoxia/reoxygenation

Pharmacological Research

Volumn 55, Issue 2, 2007, Pages 104-110

  Torii, Hiroaki ^a   Kubota, Hisashi ^a   Ishihara, Hideyuki ^a   Suzuki, Michiyasu ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Actin cytoskeleton; Adherens junction proteins; Cilostazol; Hypoxia reoxygenation; Tight junction proteins

Indexed keywords

BETA CATENIN; CILOSTAZOL; F ACTIN; PROTEIN; PROTEIN ZO1; PROTEIN ZO2; UNCLASSIFIED DRUG;

ARTICLE; BLOOD BRAIN BARRIER; CELL JUNCTION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CYTOSKELETON; DRUG POTENCY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REOXYGENATION;

ACTINS; ADHERENS JUNCTIONS; ANTIGENS, CD; BLOOD-BRAIN BARRIER; CADHERINS; CELL HYPOXIA; CELL LINE; CELL MEMBRANE PERMEABILITY; CYTOSKELETON; ENDOTHELIAL CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERCELLULAR JUNCTIONS; MEMBRANE PROTEINS; OXYGEN; PHOSPHOPROTEINS; PROTEIN TRANSPORT; TETRAZOLES; TIGHT JUNCTIONS;

EID: 33846565008     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.10.010     Document Type: Article

References (46)

1. Kambayashi J., Liu Y., Sun B., Shakur Y., Yoshitake M., and Czerwiec F. Cilostazol as a unique antithrombotic agent. Curr Pharm Des 9 (2003) 2289-2302
2. Choi J.M., Shin H.K., Kim K.Y., Lee J.H., and Hong K.W. Neuroprotective effect of cilostazol against focal cerebral ischemia via anti-apoptotic action in rats. J Pharmacol Exp Ther 300 (2002) 787-793
3. Kim K.Y., Shin H.K., Choi J.M., and Hong K.W. Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 300 (2002) 709-715
4. Kim M.J., Lee J.H., Park S.Y., Hong K.W., Kim C.D., Kim K.Y., et al. Protection from apoptotic cell death by cilostazol, phosphodiesterase type III inhibitor, via cAMP-dependent protein kinase activation. Pharmacol Res 54 (2006) 261-267
5. Nishino Y., Kashiwagi A., Takahara N., Hidaka H., and Kikkawa R. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-α in vascular endothelial cells. Horm Metab Res 29 (1997) 491-495
6. Mizutani M., Okuda Y., and Yamashita K. Effect of cilostazol on the production of platelet-derived growth factor in cultured human vascular endothelial cells. Biochem Mol Med 57 (1996) 156-158
7. Otsuki M., Saito H., Xu X., Sumitani S., Kouhara H., Kurabayashi M., et al. Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-κB binding to its recognition sequence. Atherosclerosis 158 (2001) 121-128
8. Hashimoto A, Miyakoda G, Hirose Y, Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A-and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosalerosis, in press.
9. Gloor S.M., Wachtel M., Bolliger M.F., Ishihara H., Landmann R., and Frei K. Molecular and cellular control at the blood-brain barrier. Brain Res Rev 36 (2001) 258-264
10. White B.C., Sullivan J.M., DeGracia D.J., O'Neil B.J., Neumar R.W., Grossman L.I., et al. Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. J Neurol Sci 179 (2000) 1-33
11. Karen S.M., and Davis T.P. Cerebral microvascular changes in permeability and tight junctions induced by hypoxia-reoxygenation. Am J Physiol Heart Circ Physiol 282 (2002) H1485-H1494
12. Wachtel M., Frei K., Ehler E., Bauer C., Gassmann M., and Gloor S.M. Extracellular signal-regulated protein kinaseactivation during reoxgenation is required to restore ischaemia-inducced endothelial barrier failure. Biochem J 367 (2002) 873-879
13. Witt K.A., Mark K.S., Hom S., and Davis T.P. Effects of hypoxia-reoxgenation on rat blood-brain barrier permeability and tight junctional protein expression. Am J Physiol Heart Circ Physiol 285 (2003) H2820-H2831
14. Wojciak-Stothard B., Tsang L.Y., and Haworth G. Rac and Rho play opposing roles in the regulation of hypoxia/reoxygenation-induced permeability changes in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 288 (2005) L749-L760
15. Adamson R.H., Liu B., Nilson Fry G., Rubin L.L., and Curry F.E. Microvascular permeability and number of tight junctions are modulated by cAMP. Am J Physiol 274 (1998) H1885-H1894
16. Dye J.F., Leach L., Clark P., and Firth A. Cyclic AMP and acidic fibroblast growth factor have opposing effects on tight and adherens junctions in microvascular endothelial cells in vitro. Microvasc Res 62 (2001) 94-113
17. Fan Y., Wu D.Z., Gong Y.Q., Zhou J.Y., and Hu Z.B. Effects of calycosin on the impairment of barrier function induced by hypoxia in human umbilical vein endothelial cells. Eur J Pharmacol 481 (2003) 33-40
18. Park J.H., Okayama N., Gute D., Krsmanovic A., Battarbee H., and Alexander J.S. Hypoxia/aglycemia increases endothelial permeability: role of second messengers and cytoskeleton. Am J Physiol 277 (1999) C1066-C1074
19. Rist R.J., Romero I.A., Chan M.W., Couraud P.O., Roux F., and Abbott N.J. F-actin cytoskeleton and sucrose permeability of immortalized rat brain microvascular endothelial cell monolayers: effects of cyclic AMP and astrocytic factors. Brain Res 768 (1997) 10-18
20. 207 of claudin-5 is involved in size-selective loosening of the endothelial barrier by cyclic AMP. Exp Cell Res 300 (2004) 202-212
21. Wolburg H., Neuhaus J., Kniesel U., Krauß, Schmid E.M., Öcalan M., et al. Modulation of tight junction structure in blood-brain barrier endothelial cells. Effect of tissue culture, second messengers and coculture astrocytes. J Cell Sci 107 (1994) 1347-1357
22. Yuan S.Y. Protein kinase signaling in the modulation of microvascular permeability. Vasc Res 39 (2003) 213-223
23. Lee J.H., Lee Y.K., Ishikawa M., Koga K., Fukunaga M., Miyakoda G., et al. Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats-an MRI study. Brain Res 994 (2003) 91-98
24. Weber C.C., Cai H., Ehrbar M., Kubota H., Martiny-Baron G., Weber W., et al. Effects of protein and gene transfer of the angiopoietin-1 fibrinogen-like receptor-binding domain on endothelial and vessel organization. J Biol Chem 280 (2005) 22445-22453
25. Deli M.A., Ábrahám C.S., Kataoka Y., and Niwa M. Permeability studies on in vitro blood-brain barrier models: physiology, pathology and pharmacology. Cell Mol Neurobiol 25 (2005) 59-127
26. Stelzner T.J., Weil J.V., and O'Brien R.F. Role of cyclic adenosine monophosphate in the induction of endothelial barrier properties. J Cell Physiol 139 (1989) 157-166
27. Plateel M., Dehouck M.P., Torpier G., Cecchelli R., and Teissier E. Hypoxia increases the susceptibility to oxidant stress and the permeability of the blood-brain barrier endothelial cell monolayer. J Neurochem 65 (1995) 2138-2145
28. Suttorp N., Weber U., Welsch T., and Schudt C. Role of phosphodiesterases in the regulation of endothelial permeability in vitro. J Clin Invest 91 (1993) 1421-1428
29. Warren J.B., Wilson A.J., Loi R.K., and Coughlan M.L. Opposing roles of cyclic AMP in the vascular control of edema formation. FASEB J 7 (1993) 1394-1400
30. Favot L., Keravis T., Holl V., Le Bec A., and Lugnier C. VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Haemost 90 (2003) 334-343
31. Liu F., Verin A.D., Borbiev T., and Garcia J.G. Role of cAMP-dependent protein kinase A activity in endothelial cell cytoskeleton rearrangement. Am J Physiol Lung Cell Mol Physiol 280 (2001) L1309-L1317
32. Lum H., Jaffe H.A., Schulz I.T., Masood A., RayChaudhury A., and Green R.D. Expression of PKA inhibitor (PKI) gene abolishes cAMP-mediated protection to endothelial barrier dysfunction. Am J Physiol 277 (1999) C580-C588
33. Qiao J., Huang F., and Lum H. PKA inhibits RhoA activation: a protection mechanism against endothelial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 284 (2003) L972-L980
34. Jasmina B.M., Stins M., Jovanovic S., Kim K.S., Bartus R.T., and Zlokovic B.V. Cereport™ (RMP-7) increases the permeability of human brain microvascular endothelial cell monolayers. Pharm Res 16 (1999) 1360-1365
35. Waschke J., Drenckhahn D., Adamson R.H., Barth H., and Curry F.E. cAMP protects endothelial barrier functions by preventing Rac-1 inhibition. Am J Physiol Heart Circ Physiol 287 (2004) H2427-H2433
36. Birukova A.A., Liu F., Garcia J.G., and Verin A.D. Protein kinase A attenuates endothelial cell barrier dysfunction induced by microtubule disassembly. Am J Physiol Lung Cell Mol Physiol 287 (2004) L86-L93
37. Cullere X., Shaw S.K., Andersson L., Hirahashi J., Luscinskas F.W., and Mayadas T.N. Regulation of vascular endothelial barrier function by Epac, a cAMP-activated exchange factor for Rap GTPase. Blood 105 (2005) 1950-1955
38. Fukuhara S., Sakurai A., Sano H., Yamagishi A., Somekawa S., Takakura N., et al. Cyclic AMP potentiates vascular endothelial cadherin-mediated cell-cell contact to enhance endothelial barrier function through an Epac-Rap1 signaling pathway. Mol Cell Biol 25 (2005) 136-146
39. Kooistra M.R., Corada M., Dejana E., and Bos J.L. Epac1 regulates integrity of endothelial cell junctions through VE-cadherin. FEBS Lett 579 (2005) 4966-4972
40. Guo M., Wu M.H., Granger H.J., and Yuan S.Y. Transference of recombinant VE-cadherin cytoplasmic domain alters endothelial junctional integrity and porcine microvascular permeability. J Physiol 554 (2003) 78-88
41. Krizbai I.A., Bauer H., Bresgen N., Eckl P.M., Farkas A., Szatmári E., et al. Effect of oxidative stress on the junctional proteins of cultured cerebral endothelial cells. Cell Mol Neurobiol 25 (2005) 129-139
42. Bergmann M.W., Rechner C., Freund C., Baurand A., Jamali A.E., and Dietz R. Statins inhibit reoxgenation-induced cardiomyocyte apoptosis: role for glycogen synthase kinase 3β and transcription factor β-catenin. J Mol Cell Cardiol 37 (2004) 681-690
43. Cattelino A., Liebner S., Gallini R., Zanetti A., Balconi G., Corsi A., et al. The condition inactivation of β-catenin gene in endothelial cells causes a defective vascular pattern and increased vascular fragility. J Cell Biol 162 (2003) 1111-1122
44. Venkitewaran K., Xiao K., Summers S., Calkins C.C., Vincent P.A., Pumiglia K., et al. Regulation of endothelial barrier function and growth by VE-cadherin, plakoglobin, and β-catenin. Am J Physiol Cell Physiol 283 (2002) C811-C821
45. Hino S., Tanji C., Nakayama K.I., and Kikuchi A. Phosphorylation of β-catenin by cyclic AMP-dependent protein kinase stabilizes β-catenin through inhibition of its ubiquitination. Mol Cell Biol 25 (2005) 9063-9072
46. Ishizaki T., Chiba H., Kojima T., Fujibe M., Soma T., Miyajima H., et al. Cyclic AMP induces phosphorylation of claudin-5 immunoprecipitates and expression of claudin-5 gene in blood-brain-barrier endothelial cells via protein kinase A-dependent and-independent pathways. Exp Cell Res 290 (2003) 275-288